Company / Total Debt
Pacira BioSciences, Inc. Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$372.2M
FY2025
5-year range
$372.2M / $689.5M
FY2021-FY2025
Trend
-36.4%
vs FY2024
Sector context
#32 of 83
Health Care
What the data says
At $372M, Pacira BioSciences, Inc.'s total debt ranks #52 of 83 in the Health Care sector. Total Debt has fluctuated over the past 5 years, ranging from $109M in FY2016 to $689M in FY2022.
Based on SEC 10-K filings.
$372M in FY2025 with a 3-year CAGR of -18.6%.
Improved from $522M to $372M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -18.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#52 of 83 in Health CareTop 61% of 83This company $372.2M Sector average $6.2B
▼
-93.9% below sector average
Key checks
Key Insights
- 3-year CAGR of -18.6%, indicating a declining trend.
- In FY2025, total debt decreased 36.4% year-over-year.
- Ranks #32 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $372.2M | -36.4% |
| FY2024 | $585.3M | +12.0% |
| FY2023 | $522.4M | -24.2% |
| FY2022 | $689.5M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | $108.7M | +4.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026